Poinsettia: Announcement on the company and its subsidiaries applying for comprehensive credit lines from banks
Securities code: 300723 Securities abbreviation: Poinsettia Announcement number: 2026-023
Poinsettia Pharmaceutical Group Co., Ltd.
Announcement on the company and its subsidiaries applying for comprehensive credit lines from banks
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Poinsettia Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") held the 17th meeting of the fourth board of directors on April 22, 2026, and reviewed and approved the "Proposal on the Company and its Subsidiaries' Application for Comprehensive Credit Lines from Banks". According to the company's 2026 annual budget and capital needs, the company and its subsidiaries (100% direct and indirect shareholding, the same below) plan to apply for a comprehensive credit line of RMB 3.5 billion (including the principal amount) from relevant banks. The proposal still needs to be submitted to the company's shareholders' meeting for review. The relevant matters are now announced as follows:
1. Background of applying for credit
The deadline for the company and its subsidiaries to apply for a comprehensive credit line from the bank that was approved at the eighth meeting of the company's fourth board of directors, the eighth meeting of the fourth board of supervisors, and the 2024 annual shareholders' meeting has expired. According to the company's 2026 annual budget and capital needs, in order to meet development needs and daily operating capital needs, reduce financing costs, and improve capital operation capabilities, and based on the company's actual situation, the company and its subsidiaries plan to apply for a comprehensive credit line of RMB 3.5 billion (including the original amount) from relevant banks.
2. Details of this credit grant
The credit line of RMB 3.5 billion applied to the relevant banks this time is mainly used for the daily production and operation of the company and its subsidiaries. The specific credit line shall be subject to the agreement signed by the company and its subsidiaries with the relevant banks. Within the credit period, the credit limit can be recycled. This proposal still needs to be reviewed by the company's shareholders' meeting. The credit limit applied for this time will be valid for 12 months from the date of review and approval by the shareholders' meeting.
On the premise that the comprehensive credit limit does not exceed this time, the applying shareholders' meeting authorizes the chairman to sign all legal documents within the above comprehensive credit limit (including but not limited to applications, contracts, agreements and other documents related to credit, borrowing, financing, etc.) on behalf of the company. All legal and economic responsibilities arising therefrom shall be borne by the company.
3. Documents for reference
- Resolution of the 17th meeting of the fourth session of the Board of Directors.
Announcement is hereby made.
Board of Directors of Poinsettia Pharmaceutical Group Co., Ltd.
April 23, 2026